


# GSK delivers strong Q2 sales of £8.1 billion, +6% AER, +15% CER

**Pharma**  
**£4.2bn**  
 + 12%

**Vaccines**  
**£1.6bn**  
 + 49%

**Consumer**  
**£2.3bn**  
 + 3%



All % at constant exchange rates (CER)

Total Group operating margin  
**20.7%**

Total EPS  
**27.9p** - 28%

**3**  
 new strategic R&D collaborations

Adjusted Group operating margin  
**26.7%**

Adjusted EPS  
**28.1p** + 71%

Dividend  
**19p**

“GSK delivered an excellent performance in Q2. We expect this positive momentum to continue through the second half of the year driving us towards the better end of our earnings guidance range for 2021, and meaningful performance improvement in 2022.”

**Emma Walmsley**  
 CEO, GSK

Journalists/media see press release on [www.gsk.com](http://www.gsk.com) for full details on Q2 2021. Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 68 and 69 of our second quarter 2021 earnings release..

Herpes zoster virus of shingles

